CRP and inherited lipid metabolism disorder: It has been used in several studies, including used with comorbidity data to predict kidney replacement therapy within 12 months of CKD diagnosis [59], and creation of biomarker panels using kidney measurements, dyslipidaemia biomarkers, serum sodium, and c-reactive protein to determine progressive CKD [60].